Fluorescence Property of COX-2 Imaging Compounds light up Tumors

A series of new-fangled imaging fluorescent compounds COX-2 (cyclooxygenase-2) could have wide-ranging usage in sooner detection of tumors, supervising transitioning of a tumor from pre-malignant state to more belligerent development and delineating tumor borders at the time of operative excision.

Lawrence Marnett, Ph.D, leading a group of researchers from the Vanderbilt Univ. that has endeavored to develop these compounds stated that these novel agents would soon be used in human clinical studies. Marnett explicated that COX-2 is a striking goal for molecular-based imaging. Though not observed in majority of the normal tissues, it lights up in inflammation causing tumor and lesion growths.

Marnett stated that COX-2 expression occurs in the most initial pre-cancerous phases – in pre-cancerous lesions, however not in the adjoining normal tissue and with tumor growth and augmented malignancy, its levels rise.

Compounds possessing properties of selective binding to COX-2 and carrying a fluorescent indicator or marker – ought to function as guiding light for tumor cells and inflammatory conditions.

Marnett and associates earlier illustrated that fluorescent COX-2 compounds that they presently term as ‘fluorocoxibs’ were beneficial prods for protein binding, however their earlier molecules were inapt for in-vivo imaging.

It was a challenging task for the study researchers in making a compound which is COX-2 choosy (did not bind to the correlated COX-1 enzyme), has favorable fluorescent qualities and was capable of getting in to the tissue in-vivo.

For developing these compounds, researchers began with the core chemical composition of the inflammation-combating medications celecoxib and indomethacin, then tethering varied incandescent parts of the core constitution, eventually doing synthesis of over two hundred compounds. The study team then did testing of every compound for checking how it interacts with COX-1, COX-2 proteins (after purification) and then judging favorable compounds for COX-2 selectivity and fluorescent properties in cultured cells and animal models. Successfully making the cut were duo compounds.

The researches helmed by senior study expert Brenda Crews, the researchers assessed the potentiality of such compounds in in-vivo imaging by employing 3 varied animal-based models – irritant provoked inflammation in rodent foot pad; mice after grafting human tumors in them and unprompted tumors in mouse.

In every case, the duo fluorocoxibs were administered as intravenous shots or inside their abdominal cavities – accruement occurred in the tumor tissues or having inflammation and lighting them up with fluorescence.

In the esophageal area, for instance, a pre-cancerous lesion known as Barett’s esophagus could start transitioning to a low grading and then eventually into a high grading dysplasia and ultimately into malignant cancer that has a 1-year survival rate of merely ten percent. Among people having Barrett’s esophagus, recognizing the transitioning to dysplasia is vital. The issue is that since dysplasia is not noticeably dissimilar from the pre-cancerous Barrett’s lesions, hence doctors gather arbitrary biopsy sample that could skip regions of dysplasia.

Marnett elucidated that in case a doctor can view the cells via an endoscope and observe a clump of cells light up due to such fluorocoxibs then it would be easier in identifying from where the biopsy sample could be drawn from. He further added that since levels of COX-2 rise when cancer progresses in nearly all cases of solid tumors hence it is believed that such imaging methods could have an extensive array of applications.

The researchers are presently investigating how to use these compounds for targeted delivering of chemo-therapeutic medications straight to the cells having COX-2 expression. They intend to tether a cancer-combatant medication rather than a fluorescent indicator to the core of the COX-2 inhibitor.

Popularity: 9% [?]